Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) EBT (2016 - 2025)

Integra Lifesciences Holdings' EBT history spans 17 years, with the latest figure at $4.3 million for Q4 2025.

  • For Q4 2025, EBT fell 80.88% year-over-year to $4.3 million; the TTM value through Dec 2025 reached -$563.5 million, down 2990.05%, while the annual FY2025 figure was -$563.5 million, 2989.88% down from the prior year.
  • EBT for Q4 2025 was $4.3 million at Integra Lifesciences Holdings, up from -$6.8 million in the prior quarter.
  • Across five years, EBT topped out at $67.3 million in Q1 2021 and bottomed at -$531.0 million in Q2 2025.
  • The 5-year median for EBT is $25.7 million (2023), against an average of -$3.6 million.
  • The largest annual shift saw EBT soared 2614.96% in 2021 before it crashed 3396.56% in 2025.
  • A 5-year view of EBT shows it stood at $51.8 million in 2021, then rose by 23.98% to $64.2 million in 2022, then tumbled by 55.06% to $28.9 million in 2023, then dropped by 21.89% to $22.5 million in 2024, then crashed by 80.88% to $4.3 million in 2025.
  • Per Business Quant, the three most recent readings for IART's EBT are $4.3 million (Q4 2025), -$6.8 million (Q3 2025), and -$531.0 million (Q2 2025).